Literature DB >> 34907092

Structure-Based Virtual Screening for Ligands of G Protein-Coupled Receptors: What Can Molecular Docking Do for You?

Flavio Ballante1, Albert J Kooistra1, Stefanie Kampen1, Chris de Graaf1, Jens Carlsson2.   

Abstract

G protein-coupled receptors (GPCRs) constitute the largest family of membrane proteins in the human genome and are important therapeutic targets. During the last decade, the number of atomic-resolution structures of GPCRs has increased rapidly, providing insights into drug binding at the molecular level. These breakthroughs have created excitement regarding the potential of using structural information in ligand design and initiated a new era of rational drug discovery for GPCRs. The molecular docking method is now widely applied to model the three-dimensional structures of GPCR-ligand complexes and screen for chemical probes in large compound libraries. In this review article, we first summarize the current structural coverage of the GPCR superfamily and the understanding of receptor-ligand interactions at atomic resolution. We then present the general workflow of structure-based virtual screening and strategies to discover GPCR ligands in chemical libraries. We assess the state of the art of this research field by summarizing prospective applications of virtual screening based on experimental structures. Strategies to identify compounds with specific efficacy and selectivity profiles are discussed, illustrating the opportunities and limitations of the molecular docking method. Our overview shows that structure-based virtual screening can discover novel leads and will be essential in pursuing the next generation of GPCR drugs. SIGNIFICANCE STATEMENT: Extraordinary advances in the structural biology of G protein-coupled receptors have revealed the molecular details of ligand recognition by this large family of therapeutic targets, providing novel avenues for rational drug design. Structure-based docking is an efficient computational approach to identify novel chemical probes from large compound libraries, which has the potential to accelerate the development of drug candidates.
Copyright © 2021 by The Author(s).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34907092     DOI: 10.1124/pharmrev.120.000246

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  5 in total

Review 1.  Molecular Pharmacology of P2X Receptors: Exploring Druggable Domains Revealed by Structural Biology.

Authors:  Adam C Oken; Ipsita Krishnamurthy; Jonathan C Savage; Nicolas E Lisi; Michael H Godsey; Steven E Mansoor
Journal:  Front Pharmacol       Date:  2022-06-17       Impact factor: 5.988

2.  It all clicks together: In silico drug discovery becoming mainstream.

Authors:  Antonina L Nazarova; Vsevolod Katritch
Journal:  Clin Transl Med       Date:  2022-04

Review 3.  The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs.

Authors:  Attila Egyed; Dóra Judit Kiss; György M Keserű
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

4.  Therapeutic and prognostic potential of GPCRs in prostate cancer from multi-omics landscape.

Authors:  Shiqi Li; Jianfang Chen; Xin Chen; Jin Yu; Yanzhi Guo; Menglong Li; Xuemei Pu
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

5.  Sodium or Not Sodium: Should Its Presence Affect the Accuracy of Pose Prediction in Docking GPCR Antagonists?

Authors:  Davide Bassani; Matteo Pavan; Mattia Sturlese; Stefano Moro
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.